Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Concordia Healthcare Corp. T.CXR.R

Healthcare Biotechnology


TSX:CXR.R - Post by User

Concordia Healthcare Corp.
Bullboard Posts
User Avatar Image
(3)
•••
Post by foxhunter10on Feb 20, 2015 6:07pm
166 Views
Post# 23449981

Bloom Burton & Co increases target to $64.50

Bloom Burton & Co increases target to $64.50Analyst David Martin Phd MBA, from Bloom Burton & Co, increased CXR target to $64.50 this afternoon. Notes that the CDN/USD FX has been really good for CXR since most sales are in US, whereas expeses are CDN. Also the speciality pharma comprable group mean earnings multiple has increased. Also  increased forecasted sales. Looking good! 
Bullboard Posts
Dealroom for high-potential pre-IPO opportunities